Platelet reactivity in type 2 diabetes mellitus: A comparative analysis with survivors of myocardial infarction and the role of glycaemic control

References

• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–444
   PubMed Web of Science ®Google Scholar
• Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476–1485
   PubMed Web of Science ®Google Scholar
• Patrono C. Aspirin resistance: Definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1: 1710–1713
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430–2435
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hernández-Antolin R, Moreno R, Escaned J, Alfonso F, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50: 1541–1547
   PubMed Web of Science ®Google Scholar
• Serebruany V, Pokov I, Kuliczkowski W, Chesebro J, Badimon J. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008; 100: 76–82
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Ramirez C, Costa MA, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006; 48: 298–304
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234
   PubMed Web of Science ®Google Scholar
• Gresele P, Guglielmini G, De Angelis M, Ciferri S, Ciofetta M, Falcinelli E, Lalli C, Ciabattoni G, Davì G, Bolli GB. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003; 41: 1013–1020
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589
   PubMed Web of Science ®Google Scholar
• Peace AJ, Tedesco AF, Foley DP, Dicker P, Berndt MC, Kenny D. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. J Thromb Haemost 2008; 6: 2027–2034
   PubMed Web of Science ®Google Scholar
• Peace AJ, Egan K, Kavanagh GF, Tedesco AF, Foley DP, Dicker P, Berndt MC, Kenny D. Reducing intra-individual variation in platelet aggregation: Implications for platelet function testing. J Thromb Haemost 2009; 7: 1941–1943
   PubMed Web of Science ®Google Scholar
• Peace A, McCall M, Tedesco T, Kenny D, Conroy RM, Foley D, Cox D. The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost 2010; 8: 2323–2325
   PubMed Web of Science ®Google Scholar
• Mac Mullan PA, Peace AJ, Madigan AM, Tedesco AF, Kenny D, McCarthy GM. Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine diphosphate pathway: A novel finding and potential therapeutic target. Rheumatology (Oxford) 2010; 49: 240–245
   PubMed Web of Science ®Google Scholar
• Mylotte D, Peace A, Tedesco T, Mangiacapra F, Dicker P, Kenny D, Foley DP. Clopidogrel discontinuation and platelet reactivity following coronary stenting. J Thromb Haemost 2011; 9: 24–32
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008; 31(Suppl 1)S55–S60
   PubMed Web of Science ®Google Scholar
• Malinin A, Spergling M, Muhlestein B, Steinhubl S, Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004; 15: 295–301
   PubMed Web of Science ®Google Scholar
• Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961–965
   PubMed Web of Science ®Google Scholar
• Bridges JM, Dalby AM, Millar JH, Weaver JA. An effect of D-glucose on platelet stickiness. Lancet 1965; 1: 75–77
   PubMed Web of Science ®Google Scholar
• Colwell JA, Nesto RW. The platelet in diabetes: Focus on prevention of ischemic events. Diabetes Care 2003; 26: 2181–2188
   PubMed Web of Science ®Google Scholar
• Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA 2008; 300: 2134–2141
   PubMed Web of Science ®Google Scholar
• Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEvan S, Shepherd J, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840–a1850
   PubMed Web of Science ®Google Scholar
• Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes. A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College Of Cardiology Foundation. Diabetes Care 2010; 33: 1395–1402
   PubMed Web of Science ®Google Scholar
• Hovens MM, Snoep JD, Groeneveld Y, Tamsma JT, Eikenboom JC, Huisman MV. High levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with type 2 diabetes. J Thromb Haemost 2007; 5: 1562–1564
   PubMed Web of Science ®Google Scholar
• Davi G, Catalano I, Averna M, Notarbartolo A, Ciabottoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769–1774
   PubMed Web of Science ®Google Scholar
• Cohen HW, Crandall JP, Hailpern SM, Billett HH. Aspirin resistance associated with HbA1c and obesity in diabetic patients. J Diabetes Complications 2008; 22: 224–228
   PubMed Web of Science ®Google Scholar
• Singla A, Antonino MJ, Bliden KP, Tantry US, Gurbel PA. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J 2000; 158: 784, e781–e786
   Google Scholar
• Mangiacapra F, Peace AJ, Wijns W, Barbato E. Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel. J Thromb Thrombolysis 2011; 32: 54–58
   PubMed Web of Science ®Google Scholar
• Gaborit B, Frere C, Cuisset T, Alessi MC, Dutour A. Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control. J Thromb Haemost 1009; 7: 1939–1941
   Google Scholar
• Bensoussan D, Levy Toledano S, Passa P, Caen J, Caniver J. Platelet hyperaggregation and increased plasma level of Von Willebrand factor in diabetics with retinopathy. Diabetologia 1975; 11: 307–312
   PubMed Web of Science ®Google Scholar
• van Werkum JW, Topcu Y, Postma S, Kelder JC, Hackeng CM, ten Berg JM, Verheugt FW. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel. Thromb Haemost 2008; 99: 637–639
   PubMed Web of Science ®Google Scholar
• Bernlochner I, Steinhubl S, Braun S, Morath T, Jaitner J, Stegherr J, Mehilli J, von Beckerath N, Schömig A, Kastrati A, et al. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost. 2010; 104: 1193–1200
   PubMed Web of Science ®Google Scholar